Long non-coding RNA taurine-upregulated gene 1 correlates with unfavorable prognosis in patients with refractory or relapsed acute myeloid leukemia treated by purine analogue based chemotherapy regimens

Autor:	Xing-Li Zou, Wenfeng Luo, Xun Ni, Jin Wei, Huilan Yu
Rok vydání:	2018
Předmět:	Adult Male 0301 basic medicine Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Purine analogue 03 medical and health sciences 0302 clinical medicine Refractory Internal medicine Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor Genetics Humans Medicine Cladribine Aged Chemotherapy business.industry Remission Induction Cytarabine Myeloid leukemia General Medicine Middle Aged Prognosis Fludarabine Gene Expression Regulation Neoplastic Leukemia Myeloid Acute 030104 developmental biology Purines 030220 oncology & carcinogenesis FLAG (chemotherapy) Female RNA Long Noncoding business Vidarabine medicine.drug
Zdroj:	Cancer Biomarkers. 23:485-494
ISSN:	1875-8592 1574-0153
DOI:	10.3233/cbm-181405
Popis:	OBJECTIVE This study aimed to explore the correlation of long non-coding RNA taurine-upregulated gene 1 (lncRNA TUG1) expression with clinicopathological features and its predictive value for treatment response and survival profiles in refractory or relapsed acute myeloid leukemia (R/R AML) patients. METHODS Seventy three R/R AML patients who received cladribine combined with cytarabine and granulocyte colony-stimulating factor (G-CSF) (CLAG) or fludarabine combined with cytarabine and G-CSF (FLAG) based chemotherapy and 37 non-malignant controls were recruited. LncRNA TUG1 expression was detected in bone marrow sample obtained before treatment. Complete response (CR), partial response (PR), overall response rate (ORR) and overall survival (OS) were evaluated. RESULTS LncRNA TUG1 expression was upregulated in R/R AML patients compared to controls. It was also elevated in R/R AML patients with age ⩾ 60 years (vs. age < 60 years, P= 0.030) and in patients with secondary AML (vs. primary AML, P= 0.035). R/R AML patients with lncRNA TUG1 high expression achieved numerically lower CR (P= 0.053), decreased ORR (P= 0.028) and shorter OS (P< 0.001) than patients with lncRNA TUG1 low expression. Univariate logistic regression and COX's regression disclosed that lncRNA TUG1 high expression correlated with declined ORR, numerically decreased CR, and reduced OS. Furthermore, multivariate analyses verified that lncRNA TUG1 high expression was an independent predictive factor for decreased ORR and worse OS. CONCLUSIONS In conclusion, lncRNA TUG1 expression was elevated in R/R AML patients, and it might serve as a potential biomarker for poor prognosis in R/R AML patients treated with CLAG or FLAG based chemotherapy.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3429b2bc3108d483e61723658e5c8fe0 https://doi.org/10.3233/cbm-181405 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.